Chengdu Olymvax Biopharmaceuticals Valuation

Is 688319 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 688319 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 688319 (CN¥11.73) is trading below our estimate of fair value (CN¥21.65)

Significantly Below Fair Value: 688319 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 688319?

Key metric: As 688319 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 688319. This is calculated by dividing 688319's market cap by their current revenue.
What is 688319's PS Ratio?
PS Ratio	9x
Sales	CN¥530.47m
Market Cap	CN¥4.76b

688319 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	9.2x
Enterprise Value/EBITDA	427.3x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 688319's PS Ratio compare to its peers?

The above table shows the PS ratio for 688319 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	8.2x
688293 Shanghai OPM Biosciences	16.9x	36.6%	CN¥4.9b
300653 Yantai Zhenghai Biotechnology	10.2x	14.7%	CN¥3.9b
688687 Beijing Kawin Technology Share-Holding	3.1x	20.4%	CN¥4.4b
688136 Kexing Biopharm	2.5x	27.9%	CN¥3.3b
688319 Chengdu Olymvax Biopharmaceuticals	9x	21.7%	CN¥4.8b

Price-To-Sales vs Peers: 688319 is expensive based on its Price-To-Sales Ratio (9x) compared to the peer average (8.2x).

Price to Sales Ratio vs Industry

How does 688319's PS Ratio compare vs other companies in the CN Biotechs Industry?

1 Company	Price / Sales	Estimated Growth	Market Cap
603716 Thalys Medical Technology Group	0.9x	n/a	US$242.05m

No more companies available in this PS range

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 688319 is expensive based on its Price-To-Sales Ratio (9x) compared to the CN Biotechs industry average (7.4x).

Price to Sales Ratio vs Fair Ratio

What is 688319's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

688319 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	9x
Fair PS Ratio	6.1x

Price-To-Sales vs Fair Ratio: 688319 is expensive based on its Price-To-Sales Ratio (9x) compared to the estimated Fair Price-To-Sales Ratio (6.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Jiangsu Kanion PharmaceuticalLtd

CN¥8.2b

Researches and develops, produces, and sells Chinese medicines.

600557

CN¥14.36

-4.1%

-21.9%

China Resources Double-Crane PharmaceuticalLtd

CN¥21.7b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥21.11

-5.1%

14.5%

Hunan Jiudian Pharmaceutical

CN¥12.2b

Researches, develops, produces, and sells pharmaceutical products in China and internationally.

300705

CN¥24.75

-0.1%

16.1%